NASDAQ · SEC EDGAR
Cytek Biosciences, Inc.
CTKB
Research preview · Quarterly financial statements · No price quotes · Not financial advice
Price history
4.61-78.47%5Y
Candles: each bar is one session of the published series — the body spans the open and the close, the wick the high and the low. The same bars feed the line view, so the two cannot tell different stories. Bars are sampled for the long ranges (beyond the last year the samples are month-ends), and splits are reflected while cash dividends are not, so a long series differs from a dividend-reinvested view.
Source: Daily EOD closes from the BibaMoney price store (splits reflected, cash dividends not) · 2026-09-20
What each number means
EPS acceleration is the change in year-over-year quarterly EPS growth, expressed in percentage points. Revenue growth compares matching quarters a year apart. ROE divides four consecutive quarters of net income by equity at the same latest reporting date.
The combined rank averages the EPS acceleration and ROE percentiles among issuers that carry both metrics. It ranges from 0 to 100 and describes relative position within this covered group. It is not a probability or a performance estimate.
Net margin uses four consecutive quarters with matching revenue and net income. Missing quarters stay unavailable; additive fourth-quarter values may be derived from annual minus nine-month totals known at the filing date. EPS is never derived this way.
What this data covers
Source: SEC EDGAR company facts. Each value must have been filed on or before 2026-09-20. Reporting periods older than 185 days are excluded, so a company can be listed here today and leave the screen later.
This snapshot covers 7669 listed tickers, of which 1972 carry a current reporting period and 451 carry both metrics behind the combined rank.
A missing metric stays unavailable. It is a coverage gap, not a negative assessment of the company.